MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12072-025-10871-x

Медицинская библиотека · Hepatology international · 2025

A randomized, phase Ib trial of recombinant human serum albumin in cirrhotic patients with ascites.

Wang Xinrui, Li Wanyu, Kong Fei, Guo Xiaolin, Jin Qinglong, Gao Runping, Hu Yulin, Cai Yanjun, Xin Guijie, Ji Huifan, Piao Hongxin, Fu Zhaoxu, Wang Yifei, Piao Zhiyong, Wang Siqi, Hua Rui, Wen Xiaoyu, Qi Yue, Jin Jinglan, Wang Chong, Wang Zhongfeng, Xu Fang, Zhou Qiang, Li Xu, Yu Ge, Wang Yang, Yang Tao, Xiang Wei, Pan Yu, Niu Junqi, Gao Yanhang

СтатьяКлиническое исследование I фазыРандомизированное исследованиеМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Recombinant human serum albumin (rHA) is a promising alternative to human serum albumin (HSA) for managing ascites in cirrhotic patients. This phase Ib study aims to assess the safety, tolerability, and pharmacokinetics/pharmacodynamics (PK/PD) profiles of rHA in this population.

METHODS

This randomized, open-label, phase Ib trial was conducted between December 2019 and September 2020 at 3 medical centers in China. Patients with cirrhotic ascites were randomly assigned to receive rHA or HSA at 10 g/day, 20 g/day, or 30 g/day. Each group had 12 participants (nine receiving rHA and three receiving HSA as positive control). Treatment lasted up to 14 days or until serum albumin levels reached 35 g/L, followed by a 28-day follow-up. Adverse events monitored assessed safety and tolerability, while PK/PD was evaluated by tracking serum albumin levels and plasma colloid osmotic pressure (PCOP) before and after each dose (ClinicalTrials.gov No. NCT04701697).

RESULTS

Thirty-six Chinese participants were enrolled, with 32 completing the study. The incidence of adverse events was similar between the rHA and HSA groups (44.4% vs. 44.4%, p > 0.05). Serum albumin concentration increases were comparable between groups during treatment and follow-up. While most participants experienced weight and abdominal circumference decreases, no significant dose effect was observed (p > 0.05). No anti-drug antibodies were detected.

CONCLUSION

In this study, rHA demonstrated similar safety and PK/PD to HSA in cirrhotic patients with ascites. rHA was well-tolerated, supporting the need to evaluate its safety and efficacy in a phase II clinical study.

Для цитирования: Wang Xinrui, Li Wanyu, Kong Fei, Guo Xiaolin, Jin Qinglong, Gao Runping, Hu Yulin, Cai Yanjun, Xin Guijie, Ji Huifan, Piao Hongxin, Fu Zhaoxu, Wang Yifei, Piao Zhiyong, Wang Siqi, Hua Rui, Wen Xiaoyu, Qi Yue, Jin Jinglan, Wang Chong, Wang Zhongfeng, Xu Fang, Zhou Qiang, Li Xu, Yu Ge, Wang Yang, Yang Tao, Xiang Wei, Pan Yu, Niu Junqi, Gao Yanhang. A randomized, phase Ib trial of recombinant human serum albumin in cirrhotic patients with ascites.. Hepatology international. 2025. DOI: 10.1007/s12072-025-10871-x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.